The following license files are associated with this item:
Neutralising antibody potency against SARS-CoV-2 wild- type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
- QMRO Home
- Blizard Institute
- Centre for Immunobiology
- Neutralising antibody potency against SARS-CoV-2 wild- type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
- QMRO Home
- Blizard Institute
- Centre for Immunobiology
- Neutralising antibody potency against SARS-CoV-2 wild- type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Browse
Administrators only